User login
Language
Anonymous's groups in this site
User is not a member of any group.
Your groups across all your sites
User is not a member of any group.
Recent Content
Recent Comments
- Climate researchers share theories behind apparent surge 1 week 4 days ago
- Climate change, warmer weather, blamed for Dengue fever outbreak 2 weeks 2 days ago
- WHO convening meeting to discuss Mpox status in Africa 1 month 2 weeks ago
- Writing is on the wall for the US at COP29 --BBC 1 month 2 weeks ago
Who's online
There are currently 0 users online.
You are here
Final Trial Results Confirm Ebola Vaccine Provides High Protection Against Disease
Primary tabs
who.int
23 DECEMBER 2016 | GENEVA - An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to results published today in The Lancet. The vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.
The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11 841 people in Guinea during 2015. Among the 5837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine.
The trial was led by WHO, together with Guinea’s Ministry of Health and other international partners.
Comments
First Ebola Vaccine Likely To Stop The Next Outbreak
npr.org - by Michaeleen Doucleff - December 22, 2016
. . . no vaccine — or drug for that matter — is perfect. The efficacy of the vaccine is clearly high but not "100 percent." That value reflects the fact that they just haven't tested the vaccine on enough people yet. So it is likely to decrease as the vaccine is used over time. In the end, the efficacy is likely to sit somewhere between about 70 percent and 100 percent . . .
. . . And the Ebola vaccine works lightning fast, within four or five days, he says. So it could even be given after a person is exposed to Ebola but hasn't yet developed the disease . . .
. . . “we don't know how durable the vaccine is," he says. "If you give health care workers the vaccine, for example, how long would they be protected? That's very important to learn."
(READ COMPLETE ARTICLE)